Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ranok Therapeutics' undisclosed CHAMP-related small molecule is a discovery-stage therapeutic candidate being developed for the treatment of solid tumors. The program utilizes the company's proprietary Chaperone-Mediated Protein Degrader (CHAMP) technology, which is designed to induce the selective degradation of target proteins by leveraging cellular chaperones and the ubiquitin-proteasome system. This approach aims to overcome limitations of traditional small-molecule inhibitors and other targeted protein degradation (TPD) methods, such as PROTACs, by potentially improving tumor-selective accumulation and reducing systemic toxicity. As of early 2024, the specific biological target for this exploratory program remains undisclosed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ranok Therapeutics Undisclosed CHAMP-related small molecule.